A population-based study of the clinical expression of the hemochromatosis gene

New England Journal of Medicine

Volumn 341, Issue 10, 1999, Pages 718-724

  Olynyk, John K ^a,b,e   Cullen, Digby J ^b   Aquilia, Sina ^b   Rossi, Enrico ^c   Summerville, Lesa ^d   Powell, Lawrie W ^d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e University Department of Medicine   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ADULT; AGED; ARTICLE; CHROMOSOME 6; CLINICAL FEATURE; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GENE EXPRESSION; GENE MUTATION; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; FERRITINS; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HOMOZYGOTE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION, MISSENSE; PENETRANCE; PREVALENCE; TRANSFERRIN; WESTERN AUSTRALIA;

EID: 0033517343     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199909023411002     Document Type: Article

References (36)

1. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990;74:525-30.
2. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998;43:830-6.
3. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999;116:193-207.
4. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
5. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13:399-408.
6. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996;22:187-94.
7. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-52.
8. Barton JC, Shih WW, Sawada-Hirai R, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997;23:135-45.
9. Adams PC, Campion ML, Gandon G, LeGall JY, David V, Jouanolle AM. Clinical and family studies in genetic hemochromatosis: microsatellite and HFE studies in five atypical families. Hepatology 1997;26:986-90.
10. The UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997;41:841-4.
11. Borot N, Roth M-P, Malfroy L, et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 1997;45:320-4.
12. Carella M, D'Ambrosio L, Totaro A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997; 60:828-32.
13. Cardoso EMP, Stal P, Hagen K, et al. HFE mutations in patients with hereditary hemochromatosis in Sweden. J Intern Med 1998;243:203-8.
14. Rossi E, Henderson S, Chin CY, et al. Genotyping as a diagnostic aid in genetic haemochromatosis. J Gastroenterol Hepatol 1999;14:427-30.
15. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and in patients with liver disease. Ann Intern Med 1999;130:953-62.
16. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999;116: 372-7.
17. Olynyk JK, Bacon BR. Hereditary hemochromatosis: detecting and correcting iron overload. Postgrad Med 1994;96:151-8, 161, 165.
18. Bassett ML, Halliday JW, Bryant S, Dent O, Powell LW. Screening for hemochromatosis. Ann N Y Acad Sci 1988;526:274-89.
19. Beilby J, Olynyk J, Ching S, et al. Transferrin index: an alternative method for calculating the iron saturation of transferrin. Clin Chem 1992; 38:2078-81.
20. McLaren CE, McLachlan GJ, Halliday JW, et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 1998;114:543-9.
21. Powell LW, Summers KM, Board PG, Axelsen E, Webb S, Halliday JW. Expression of hemochromatosis in homozygous subjects: implications for early diagnosis and prevention. Gastroenterology 1990;98:1625-32.
22. Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998;114:1003-8.
23. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998;114:319-23.
24. Welborn TA, Curnow DH, Wearne JT, Cullen KJ, McCall MG, Stenhouse NS. Diabetes detected by blood-sugar measurement after a glucose load: report from the Busselton survey, 1966. Med J Aust 1968;2:778-83.
25. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J Epidemiol Community Health 1997;51:515-9.
26. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24-9.
27. Use of chelex to improve the PCR signal from a small number of cells. In: Singer-Sam J, Tanguay R. Amplifications, a forum for PCR users. Issue 3, 1989.
28. Cullen LM, Summerville L, Glassick TV, Crawford DH, Powell LW, Jazwinska EC. Neonatal screening for the hemochromatosis defect. Blood 1997;90:4236-7.
29. Jeffrey GP, Chakrabarti S, Megele RA, Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet (in press).
30. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University Press, 1967.
31. Searle J, Kerr JRF, Halliday JW, Powell LW. Iron storage disease. In: MacSween RNM, Anthony PP, Scheuer PJ, Burt AD, Portmann BC, eds. Pathology of the liver. London: Churchill Livingstone, 1994:224.
32. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34:275-8.
33. Mendler MH, Moirand R, Turlin B, et al. Study of HFE mutations in the "dysmetabolic iron overload syndrome." Hepatology 1998;28:Suppl: 419A. abstract.
34. Powell LW, Jazwinska E, Halliday JW. Primary iron overload. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease. London: Saunders, 1994:227-70.
35. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998;280:172-8.
36. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasivc prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998;115:929-36.